← Back to Screener
Decoy Therapeutics Inc. Common Stock (DCOY)
Price$6.61
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-49.33%
Price vs S&P 500 (4W)15.57%
VGM Score21.49
Market Capitalization$3.52M
All Metrics
Book Value / Share (Quarterly)$87.47
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-147.41
Price vs S&P 500 (YTD)-23.31%
Gross Margin (TTM)48.62%
Net Profit Margin (TTM)-179.05%
EPS (TTM)$-1011.67
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-1011.67
EPS (Annual)$-5.79
ROI (Annual)-321.56%
Gross Margin (Annual)48.61%
Net Profit Margin (5Y Avg)-1270.39%
Cash / Share (Quarterly)$176.42
ROA (Last FY)-184.45%
EBITD / Share (TTM)$-619.84
ROE (5Y Avg)-195.30%
Operating Margin (TTM)-179.62%
Cash Flow / Share (Annual)$-108.89
P/B Ratio0.91x
P/B Ratio (Quarterly)0.90x
Net Income / Employee (Annual)$-506,900
ROA (TTM)-193.31%
EPS Incl Extra (Annual)$-5.79
Current Ratio (Annual)2.13x
Quick Ratio (Quarterly)1.72x
3-Month Avg Trading Volume0.02M
52-Week Price Return-95.13%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)1.91x
Asset Turnover (Annual)0.05x
52-Week High$415.80
Operating Margin (5Y Avg)-1288.41%
EPS Excl Extra (Annual)$-5.79
26-Week Price Return-41.40%
Quick Ratio (Annual)2.07x
13-Week Price Return-5.57%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.84x
Enterprise Value$-4.30M
Asset Turnover (TTM)0.13x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-693.85%
Cash / Share (Annual)$241.60
3-Month Return Std Dev98.81%
Net Income / Employee (TTM)$-1,184,900
ROE (Last FY)-368.77%
EPS Basic Excl Extra (Annual)$-5.79
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1011.67
Receivables Turnover (Annual)0.00x
ROI (TTM)-258.50%
P/S Ratio (TTM)0.75x
Pretax Margin (5Y Avg)-1270.40%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-119.50%
Year-to-Date Return-15.15%
5-Day Price Return-20.93%
EPS Normalized (Annual)$-5.79
ROA (5Y Avg)-130.27%
Net Profit Margin (Annual)-693.85%
Month-to-Date Return-25.90%
EBITD / Share (Annual)$-5.96
Operating Margin (Annual)-696.28%
ROI (5Y Avg)-183.25%
EPS Basic Excl Extra (TTM)$-1011.67
P/B Ratio (Annual)0.71x
Inventory Turnover (TTM)1.39x
Pretax Margin (TTM)-179.05%
Book Value / Share (Annual)$132.84
Price vs S&P 500 (13W)-13.83%
Beta0.63x
Revenue / Share (TTM)$0.00
ROE (TTM)-258.50%
52-Week Low$4.32
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Oct 2024
Nov 2024
Dec 2024
Jan 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DCOYDecoy Therapeutics Inc. Common Stock | — | — | D | $6.61 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Decoy Therapeutics is a preclinical-stage biotechnology company developing peptide conjugate therapeutics for respiratory viruses and gastrointestinal cancers. The company combines machine learning and artificial intelligence with high-throughput synthesis to accelerate drug discovery and candidate optimization.